---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-033364"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2026-07-15T20:18:23+00:00"
generated_at: "2026-07-15T20:19:11.065154+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma settles $398,740 claims via share issuance; creates Series N preferred with 75M votes per share

## Summary
- Court approved settlement with Trillium Partners: Regen will issue shares (common or Series A preferred) to satisfy $398,740 in claims; shares sold by plaintiff, 65% of net proceeds to plaintiff.
- Potential dilution: number of shares indeterminable; as of April 17, 2026, common shares outstanding ~402.9M; CEO David Koos is a creditor and will be paid after one year.
- Created Series N Preferred Stock: 1,000 shares authorized, each with 75 million votes, enabling concentrated voting control.
- Changed auditor: BCRG replaced by Simon & Edward LLP after acquisition; no disagreements, but prior reports had going concern qualification.

## SEC filing metadata
- accession: 0001493152-26-033364
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2026-07-15T20:18:23+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000149315226033364/0001493152-26-033364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000149315226033364/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-033364
- JSON: https://secwatch.observer/filing/0001493152-26-033364.json
- Plain text: https://secwatch.observer/filing/0001493152-26-033364.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.